-
Electronic (PDF)
-
Site License
-
Enterprisewide
Diphtheria - Pipeline Review, Q2 2011
Global Markets Direct, April 2011, Pages: 54
Diphtheria - Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, 'Diphtheria - Pipeline Review, Q2 2011', provides an overview of the Diphtheria therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diphtheria. 'Diphtheria - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Diphtheria.
- A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diphtheria pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Diphtheria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Diphtheria therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diphtheria Overview
Therapeutics Development
An Overview of Pipeline Products for Diphtheria
Diphtheria Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Diphtheria Therapeutics - Products under Development by Companies
Companies Involved in Diphtheria Therapeutics Development
Sanofi-Aventis
GlaxoSmithKline plc
Merck & Co., Inc.
LG Life Sciences, Ltd
Diphtheria - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
251154 Vaccine + Synflorix + Rotarix + Infanrix Hexa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V501 + Menactra + Adacel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK1024850A + GSK2202083A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actacel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTaP-Hep B-PRP-T Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2202083A + Synflorix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CombAct-HIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CombAct-HIB + OPV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heptavalent Combination Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hexavalent Combination Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infanrix-IPV/Hib + Engerix-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK217744 Formulation B + Prevenar 13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ProQuad + Infanrix Hexa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK217744 Formulation A + Prevenar 13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hexaxim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PR5I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quadracel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTaP-HepB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DtwP-HB-Hib (liq) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DtwP-HB-Hib (recon) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DtwP-HB vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diphtheria Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Diphtheria, Q2 2011
Products under Development for Diphtheria – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Sanofi-Aventis, 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
LG Life Sciences, Ltd, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Diphtheria Therapeutics – Drug Profile Updates
List of Figures
Number of Products under Development for Diphtheria, Q2 2011
Products under Development for Diphtheria – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
